Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (141-150 of 164) with videos related to

Pageof 17
Sort By:
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
American Journal of Hematology|June 21, 2021
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)Grégory Lazarian, Michaël Munger, Anne Quinquenel, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Blood Cancer Journal|May 29, 2020
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-upJerome Paillassa, Edouard Cornet, Stephanie Noel, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Cancer Cell|September 22, 2023
ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndromeErin M Parry, Camilla K Lemvigh, Stephanie Deng, et al.
Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
The New England Journal of Medicine|September 6, 2018
Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaFranck Morschhauser, Nathan H Fowler, Pierre Feugier, et al.
Blood Cancer Journal|October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
Pageof 17

Showing results (141-150 of 164) with videos related to

Sort By:
Pageof 17
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
American Journal of Hematology|June 21, 2021
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)Grégory Lazarian, Michaël Munger, Anne Quinquenel, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Blood Cancer Journal|May 29, 2020
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-upJerome Paillassa, Edouard Cornet, Stephanie Noel, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Cancer Cell|September 22, 2023
ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndromeErin M Parry, Camilla K Lemvigh, Stephanie Deng, et al.
Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
The New England Journal of Medicine|September 6, 2018
Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaFranck Morschhauser, Nathan H Fowler, Pierre Feugier, et al.
Blood Cancer Journal|October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
Pageof 17